| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As an amino acid derivative, H-DL-Phe(4-Me)-OH does not have a defined primary drug target in the context of therapeutic development. However, as a phenylalanine analogue with a methyl substituent, it may be used in research to study neurotransmitter receptors, particularly dopamine and norepinephrine receptors where phenylalanine derivatives can serve as ligands. The methyl group can modulate the compound's physicochemical properties, receptor binding affinity, and metabolic stability. The compound can also serve as a building block for synthesizing peptides with modified pharmacological properties and as a replacement for aromatic amino acid residues in polypeptide analogues.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on amino acid derivatives, including this phenylalanine analogue, have demonstrated their capacity to influence the release of anabolic hormones, modulate fuel availability for cellular activity, enhance mental performance under stress-related conditions, and prevent exercise-induced muscle damage. As a phenylalanine derivative, this compound may be used in cell-based assays to investigate amino acid transport mechanisms, neurotransmitter synthesis, and the effects of methyl substitution on peptide stability and biological activity. The compound can also be utilized in studies examining the role of phenylalanine in neurotransmission and as a precursor for catecholamine synthesis. |
| ln Vivo |
In vivo studies on amino acid derivatives have shown that they affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. As a phenylalanine analogue, this compound may be administered in animal studies to evaluate the effects of methyl-substituted phenylalanine on neurological function or to study the pharmacokinetics and bioavailability of modified amino acids. However, specific in vivo pharmacological data for this exact compound remains limited, as it is primarily supplied as a research chemical for peptide synthesis and drug design.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve studies with purified receptors or enzymes to evaluate the effects of methyl substitution on binding affinity. Standard protocols include radioligand binding assays using membrane preparations from brain tissue or cells expressing recombinant receptors. The compound can be tested for its ability to compete with radiolabeled ligands for receptor binding. For enzyme studies, the compound may be evaluated as a substrate or inhibitor for enzymes involved in phenylalanine metabolism, such as phenylalanine hydroxylase or tyrosine aminotransferase.
|
| Cell Assay |
Cell-based assays for this phenylalanine derivative typically utilize neuronal cell lines or primary neurons to evaluate compound effects on neurotransmitter synthesis and receptor function. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or LDH release assays. The compound's effects on neurotransmitter levels can be measured using HPLC or mass spectrometry. For peptide synthesis applications, the compound is used as a building block for synthesizing peptide inhibitors or bioactive compounds.
|
| Animal Protocol |
In vivo animal studies for amino acid derivatives typically involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models (mice or rats). Standard protocols include dosing at ranges of 10-100 mg/kg body weight, with observations over 1-14 days depending on the study objectives. For studies evaluating the effects of phenylalanine analogues on neurological function, animals may be administered the compound and monitored for behavioral changes, cognitive performance, or neurotransmitter levels. Pharmacodynamic assessments may include brain tissue collection for neurotransmitter measurement and monitoring of body weight and general health parameters. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this phenylalanine derivative can be inferred from structurally related compounds. As a small molecule (molecular weight 179.22 g/mol), it is expected to have reasonable oral bioavailability. The methyl substituent may influence the compound's lipophilicity and metabolic stability compared to phenylalanine. The compound shows moderate solubility in aqueous and organic solvents. For in vivo administration, formulations using suitable co-solvent systems may be employed. The compound is stable at room temperature during shipping and should be stored as powder at -20°C for long-term preservation. Definitive PK parameters such as half-life, Cmax, and AUC require formal studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. Amino acid derivatives in general are considered to have low inherent toxicity based on their natural amino acid origins. However, as with all research chemicals, appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL). For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays.
|
| References | |
| Additional Infomation |
4-Methylphenylalanine is a compound for which no isomer has been specified; its structural formula is given in the first source.
H-DL-Phe(4-Me)-OH is a phenylalanine analogue featuring a methyl substituent on the phenyl ring. The methyl group alters the molecule's physicochemical properties, making it useful in the development of specific peptide inhibitors or bioactive compounds. It is often employed in research related to bioactive peptides, drug design, and molecular studies in therapeutic applications. It can serve as a replacement for aromatic amino acid residues in polypeptide analogues to determine agonist or antagonist pharmacological properties. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes. |
| Molecular Formula |
C10H13NO2
|
|---|---|
| Molecular Weight |
179.22
|
| Exact Mass |
179.094
|
| CAS # |
4599-47-7
|
| PubChem CID |
409319
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
323.5±30.0 °C at 760 mmHg
|
| Melting Point |
277ºC
|
| Flash Point |
149.5±24.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.568
|
| LogP |
1.57
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
174
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)CC(C(=O)O)N
|
| InChi Key |
DQLHSFUMICQIMB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H13NO2/c1-7-2-4-8(5-3-7)6-9(11)10(12)13/h2-5,9H,6,11H2,1H3,(H,12,13)
|
| Chemical Name |
2-amino-3-(4-methylphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5797 mL | 27.8987 mL | 55.7973 mL | |
| 5 mM | 1.1159 mL | 5.5797 mL | 11.1595 mL | |
| 10 mM | 0.5580 mL | 2.7899 mL | 5.5797 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
